ncRNA basic information ncRNA ID: MIMAT0000077 ncRNA Database: miRBase ncRNA Name: miR-22-3p ncRNA Type: miRNA ncRNA Expression: up-regulated ncRNA Method: qRT-PCR ncRNA Target Gene: NET1 ncRNA Pathway: NA Evidence (ncRNA-drug): validated

drug basic information Drug ID: DB00997 (APRD00185, DB05331, DB05847) Drug Name: Adriamycin Drug Method: In the present study, we measured the chemosensitivity of five bladder cancer (BCa) cell lines to seven commonly used chemotherapeutic drugs by Vita-Blue assay. We then identified the most sensitive (5637) and most tolerant cell lines (H-bc) and conducted a multi-group test. This test included expression group analyses of coding and non-coding genes (miR-omic and RNA-seq). Based on our analyses, we selected miR-22-3p as a target. We then determined its own target gene [neuroepithelial cell transforming 1 (NET1)] by bioinformatic analysis and confirmed this finding by TaqMan-quantitative reverse transcription polymerase chain reaction (qRT-PCR), western blot analysis and luciferase reporter assay. The effect of miR-22-3p on BCa multi-chemoresistance was also determined by transfecting cells with the miR-22-3p-mimic or miR-22-3p antagomiR. We assessed the involvement of NET1 in BCa chemoresistance by siRNA-mediated NET1 inhibition or pINDUCER21-enhanced green fluorescent protein NET1 mediated overexpression. Plate colony formation and apoptosis assays were conducted to observe the effects of miR-22-3p and NET1 on BCa chemoresistance. In conclusion, our results suggest that miR-22-3p promotes BCa chemoresistance by targeting NET1 and may serve as a new prognostic biomarker for BCa patients. Drug Response: resistant

Cancer basic information Cancer: bladder cancer Tissue/Cell: cell line ( 5637,T24,m-Uc-3, J82,H-bc)

Other information Title: miR-22-3p enhances multi-chemoresistance by targeting NET1 in bladder cancer cells. Journal: Oncol Rep Published: 2018 PubMed ID: 29620229